Bradley J. Monk, MD
An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without modification, according to VBL therapeutics, the company developing the novel anticancer gene therapy.1
“We are very pleased by the outcome of this [phase III] interim analysis, which demonstrates the potential benefit of VB-111 over standard-of-care in a randomized-controlled study,” Dror Harats, MD, chief executive officer of VBL, said in the press release. “The OVAL phase III interim data are at least as good as the CA-125 response results observed in our VB-111 phase II study, which enrolled a similar patient population. This encouraging interim result adds to the promising data seen with VB-111 across our phase II studies in multiple indications.”
- VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study. Published online March 26, 2020. https://bit.ly/2WKzijW. Accessed March 26, 2020.
- VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer. Published online June 3, 2019. https://bit.ly/3axNS2x. Accessed March 26, 2020.
... to read the full story